Income Statement

LIGAND PHARMACEUTICALS INC

LGND
Annual
Performance Overview Click any row in the table to add it to this chart
in millions USD
Metric Dec 31, 2025 2025 FY Dec 31, 2024 2024 FY Dec 31, 2023 2023 FY Dec 31, 2022 2022 FY Dec 31, 2021 2021 FY Dec 31, 2020 2020 FY Dec 31, 2019 2019 FY Dec 31, 2018 2018 FY Dec 31, 2017 2017 FY Dec 31, 2016 2016 FY Dec 31, 2015 2015 FY Dec 31, 2014 2014 FY Dec 31, 2013 2013 FY Dec 31, 2012 2012 FY Dec 31, 2011 2011 FY
Revenue
268.09 167.13 131.31 196.25 277.13 186.42 120.28 251.45 141.10 108.97 71.91 64.54 48.97 31.39 30.04
Cost of Revenue
- - - - - - - 6.34 - - - - - - -
Gross Profit
268.09 167.13 131.31 196.25 277.13 186.42 120.28 245.12 141.10 108.97 71.91 64.54 48.97 31.39 30.04
Operating Expenses
227.09 189.74 121.49 193.21 198.24 177.69 126.00 87.73 73.03 65.09 44.59 44.91 34.03 30.81 32.44
Research & Development
81.18 21.43 24.54 36.08 69.01 59.39 55.91 27.86 26.89 21.22 13.38 12.12 9.27 10.79 10.29
Selling, General & Administrative
92.45 78.65 52.79 70.06 57.48 64.44 41.88 37.73 28.65 26.62 24.38 22.57 17.98 16.11 14.98
Other Operating Expenses
- - - - - - - - - - - - - - -
Operating Income
41.00 -22.61 9.82 3.04 78.90 8.73 -5.72 157.39 68.08 43.89 27.33 19.63 14.94 0.57 -2.40
Non-Operating Income
117.96 25.12 51.72 32.97 -31.60 -36.38 -10.44 9.60 -10.85 -35.93 8.00 -8.32 -5.74 -4.44 -2.25
Interest Income
13.66 8.06 7.71 2.05 0.89 8.08 28.43 - - - - - - - 0.03
Interest Expense
2.40 - 0.66 1.80 19.63 27.42 35.75 48.28 - - - 4.86 2.08 3.31 2.51
Other Non-Op Income / Expense
-0.09 -54.92 -1.95 4.19 -8.86 -0.11 -5.10 -6.31 -2.05 -23.13 -5.14 1.67 -0.06 0.52 0.63
Income Before Tax
158.96 28.37 63.66 36.01 47.30 -10.54 796.64 173.33 57.23 7.96 35.33 11.30 9.21 -3.87 -2.95
Income Tax Expense
34.51 6.55 11.51 69.37 -9.84 -7.55 167.34 30.01 44.68 9.60 -221.98 -0.72 -0.05 -3.34 -13.13
Non-Controlling Interest
- - - - - - - - 0.00 0.00 -2.38 -1.13 - - -
Net Income
124.45 -4.03 52.15 -33.36 57.14 -2.99 629.30 143.32 12.56 -1.64 257.31 12.02 -11.42 -0.53 10.18
Supplemental Per share data, derived & other items — not part of the income statement
in millions USD unless noted
Metric Dec 31, 2025 2025 FY Dec 31, 2024 2024 FY Dec 31, 2023 2023 FY Dec 31, 2022 2022 FY Dec 31, 2021 2021 FY Dec 31, 2020 2020 FY Dec 31, 2019 2019 FY Dec 31, 2018 2018 FY Dec 31, 2017 2017 FY Dec 31, 2016 2016 FY Dec 31, 2015 2015 FY Dec 31, 2014 2014 FY Dec 31, 2013 2013 FY Dec 31, 2012 2012 FY Dec 31, 2011 2011 FY
Depreciation & Amortization
- - - - - - - - - - - - - - -
EBITDA
74.78 12.63 46.34 54.57 129.97 34.42 12.64 172.11 79.79 55.18 29.96 22.28 17.61 3.30 0.39
Earnings Per Share (Basic)
6.44 -0.22 3.02 -1.98 3.44 -0.18 33.13 6.77 0.60 -0.08 13.00 0.59 0.56 - -
Diluted EPS
6.13 -0.22 2.94 -1.98 3.31 -0.18 31.85 5.96 0.53 -0.08 12.12 0.56 0.55 - -
Weighted Average Shares
19.34 18.29 17.30 16.87 16.63 16.19 19.00 21.16 21.03 20.83 19.79 20.42 20.31 19.85 19.66
Diluted Weighted Avg Shares
20.29 18.29 17.76 16.87 17.25 16.19 19.76 24.07 23.48 20.83 21.23 21.43 20.75 19.85 19.71
Comprehensive Income
138.85 -9.16 52.32 -33.43 57.02 -3.57 630.11 142.47 12.30 -3.80 257.27 14.06 14.33 -0.53 -